|
1
|
Varkaris A, Gunturu K, Kewalramani T and
Tretter C: Acute myeloid leukemia after radium-223 therapy: Case
report. Clin Genitourin Cancer. 15:e723–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang L, Wang SA, DiNardo C, Li S, Hu S,
Xu J, Zhou W, Goswami M, Medeiros LJ and Tang G:
Tetraploidy/near-tetraploidy acute myeloid leukemia. Leuk Res.
53:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamaguchi H: Gene mutations in acute
myeloid leukemia. Rinsho Ketsueki. 57:2535–2542. 2016.(In
Japanese). PubMed/NCBI
|
|
4
|
Uchida T, Hagihara M, Hua J and Inoue M:
The effects of azacitidine on the response and prognosis of
myelodysplastic syndrome and acute myeloid leukemia involving a
bone marrow erythroblast frequency of >50. Leuk Res. 53:35–38.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao SY, Tuerxun N, Chen R and Hao JP:
Analysis of therapy and efficacy after remission of acute myeloid
leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:1721–1724.
2016.(In Chinese). PubMed/NCBI
|
|
6
|
Liu C, Zhao L, Zhao J, Xu Q, Song Y and
Wang H: Reduced ADAMTS-13 level negatively correlates with
inflammation factors in plasma of acute myeloid leukemia patients.
Leuk Res. 53:57–64. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Montewis A and Eveillard M: Acute myeloid
leukemia with erythrophagocytosis indicative of KAT6A
rearrangement. Blood. 128:3142016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pradhan AK, Halder A and Chakraborty S:
Physical and functional interaction of the proto-oncogene EVI1 and
tumor suppressor gene HIC1 deregulates Bcl-xL mediated block in
apoptosis. Int J Biochem Cell Biol. 53:320–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Louz D, van den Broek M, Verbakel S,
Vankan Y, van Lom K, Joosten M, Meijer D, Löwenberg B and Delwel R:
Erythroid defects and increased retrovirally-induced tumor
formation in Evi1 transgenic mice. Leukemia. 14:1876–1884. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nanjundan M, Nakayama Y, Cheng KW, Lahad
J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW and
Mills GB: Amplification of MDS1/EVI1 and EVI1, located in the
3q26.2 amplicon, is associated with favorable patient prognosis in
ovarian cancer. Cancer Res. 67:3074–3084. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jazaeri AA, Ferriss JS, Bryant JL, Dalton
MS and Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as
potential therapeutic targets in ovarian cancer. Gynecol Oncol.
118:189–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heller G, Rommer A, Steinleitner K, Etzler
J, Hackl H, Heffeter P, Tomasich E, Filipits M, Steinmetz B,
Topakian T, et al: EVI1 promotes tumor growth via transcriptional
repression of MS4A3. J Hematol Oncol. 8:282015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao JS, Zhang Y, Tang X, Tucker LD,
Tarwater PM, Quesenberry PJ, Rigoutsos I and Ramratnam B: The Evi1,
microRNA-143, K-Ras axis in colon cancer. FEBS Lett. 585:693–699.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nayak KB, Kuila N, Das Mohapatra A, Panda
AK and Chakraborty S: EVI1 targets ΔNp63 and upregulates the cyclin
dependent kinase inhibitor p21 independent of p53 to delay cell
cycle progression and cell proliferation in colon cancer cells. Int
J Biochem Cell Biol. 45:1568–1576. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Xiao X, Liang Y, Peng M, Jiang Y,
Xu Y and Gong G: Effect of methylation inhibitor on demethylation
pattern of the PD-1 gene in promoter region and PD-1 expression in
human T lymphocyte cell line. Zhong Nan Da Xue Xue Bao. Yi Xue Ban.
36:1163–1169. 2011.(In Chinese).
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Banerjee S, Yang S and Foster CB: A
luciferase reporter assay to investigate the differential
selenium-dependent stability of selenoprotein mRNAs. J Nutr
Biochem. 23:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pham MH, Kondapalli N, Reckord CL and
Foglesong PD: Interleukin-2 induces the activities of DNA
topoisomerase I and DNA topoisomerase II in HuT 78 cells. Biochem
Biophys Res Commun. 390:577–580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yue X, Zhao Y, Zhang C, Li J, Liu Z, Liu J
and Hu W: Leukemia inhibitory factor promotes EMT through
STAT3-dependent miR-21 induction. Oncotarget. 7:3777–3790. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Humbert L, Ghozlan M, Canaff L, Tian J and
Lebrun JJ: The leukemia inhibitory factor (LIF) and p21 mediate the
TGFβ tumor suppressive effects in human cutaneous melanoma. BMC
Cancer. 15:2002015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noordermeer SM, Monteferrario D, Sanders
MA, Bullinger L, Jansen JH and van der Reijden BA: Improved
classification of MLL-AF9-positive acute myeloid leukemia patients
based on BRE and EVI1 expression. Blood. 119:4335–4337. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vázquez I, Maicas M, Cervera J, Agirre X,
Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito
M, Carranza C, et al: Down-regulation of EVI1 is associated with
epigenetic alterations and good prognosis in patients with acute
myeloid leukemia. Haematologica. 96:1448–1456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balgobind BV, Lugthart S, Hollink IH,
Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D,
Creutzig U, Kaspers GJ, de Bont ES, et al: EVI1 overexpression in
distinct subtypes of pediatric acute myeloid leukemia. Leukemia.
24:942–949. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weisser M, Haferlach C, Haferlach T and
Schnittger S: Feasibility of using the combined MDS-EVI1/EVI1 gene
expression as an alternative molecular marker in acute myeloid
leukemia: A report of four cases. Cancer Genet Cytogenet.
177:64–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gröschel S, Lugthart S, Schlenk RF, Valk
PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF,
Lübbert M, et al: High EVI1 expression predicts outcome in younger
adult patients with acute myeloid leukemia and is associated with
distinct cytogenetic abnormalities. J Clin Oncol. 28:2101–2107.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Glass C, Wuertzer C, Cui X, Bi Y, Davuluri
R, Xiao YY, Wilson M, Owens K, Zhang Y and Perkins A: Global
identification of EVI1 target genes in acute myeloid leukemia. PloS
One. 8:e671342013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kutok JL, Yang X, Folkerth R and Adra CN:
Characterization of the expression of HTm4 (MS4A3), a cell cycle
regulator, in human peripheral blood cells and normal and malignant
tissues. J Cell Mol Med. 15:86–93. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan L, Ren F, Rong M, Dang Y, Luo Y, Luo D
and Chen G: Correlation between down-expression of miR-431 and
clinicopathological significance in HCC tissues. Clin Transl Oncol.
17:557–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu XT: TGFbeta-mediated formation of
pRb-E2F complexes in human myeloid leukemia cells. Biochem Biophys
Res Commun. 369:277–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
